FA
NBIX icon

FDx Advisors’s Neurocrine Biosciences NBIX Stock Holding History

FDx Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,011
Closed -$265K – 545
2023
Q4 		$265K Buy
+2,011
New +$231K 0.02% 560
2023
Q2 		– Sell
-3,159
Closed -$377K – 810
2023
Q1 		$377K Hold
3,159
– – 0.02% 483
2022
Q4 		$377K Sell
3,159
-329
-9% -$38.5K 0.02% 483
2022
Q3 		$370K Sell
3,488
-1,549
-31% -$157K 0.02% 483
2022
Q2 		$491K Sell
5,037
-576
-10% -$53.2K 0.02% 483
2022
Q1 		$526K Buy
5,613
+2,729
+95% +$231K 0.02% 490
2021
Q4 		$246K Sell
2,884
-2,179
-43% -$200K 0.01% 771
2021
Q3 		$486K Buy
5,063
+621
+14% +$58.7K 0.02% 524
2021
Q2 		$432K Buy
4,442
+167
+4% +$16K 0.01% 547
2021
Q1 		$416K Buy
4,275
+1,588
+59% +$167K 0.02% 516
2020
Q4 		$258K Buy
2,687
+312
+13% +$30.1K 0.01% 614
2020
Q3 		$228K Buy
+2,375
New +$275K 0.01% 556

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FDx Advisors's NBIX Position: Q1 2024 in Review

FDx Advisors sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 2,011 shares — an estimated $265K sold.

FDx Advisors first reported a position in NBIX in Q3 2020 and held it in 12 quarters. The position peaked at $526K in Q1 2022. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • FDx Advisors reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
  • FDx Advisors sold 2,011 Neurocrine Biosciences shares in Q1 2024, an estimated $265K.
  • FDx Advisors first reported a position in Neurocrine Biosciences in Q3 2020 and held it in 12 quarters.
  • FDx Advisors's Neurocrine Biosciences position peaked at $526K in Q1 2022.
  • 589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on FDx Advisors's 13F filing for Q1 2024, filed 3 May 2024.